# Tinea Pedis

Confirm atypical, chronic, or treatment-refractory foot eruptions with potassium hydroxide examination, then match topical therapy duration to interdigital versus hyperkeratotic disease. Escalate persistent disease by reassessing diagnosis, nail reservoir, adherence, immunologic risk, bacterial superinfection, and need for culture-directed evaluation.

**Clinical question:** How should clinicians confirm, treat, and prevent recurrent or refractory tinea pedis?

Updated: 2026-09-15T23:54:02.632388+00:00

## What matters in practice
- Use potassium hydroxide examination of scale when the morphology is atypical, disease is hyperkeratotic, or treatment has failed; branching hyphae support dermatophyte infection. [2][4][6][15]
- For limited disease, topical terbinafine 1% twice daily for 1-2 weeks is a supported first-line regimen; miconazole requires 3-4 weeks. [22]
- Interdigital disease may respond within 1 week, whereas hyperkeratotic moccasin-type disease commonly requires about 4 weeks because keratin limits topical penetration. [11][12][15]
- For refractory disease, obtain fungal culture, examine and address concomitant onychomycosis, and reassess for bacterial toe-web infection, immune deficiency, resistance, or an alternative inflammatory diagnosis. [12][17][20]
- Avoid nystatin for tinea pedis because it is ineffective against dermatophytes. [11]

## Identify the pattern that changes testing and treatment duration

Classify the distribution before selecting a regimen or assuming treatment failure.

Interdigital tinea pedis typically presents in toe webs, while hyperkeratotic disease produces chronic scaly erythema across the plantar and lateral foot in a moccasin distribution. Vesicular or bullous disease may involve the sole. Hyperkeratotic disease is frequently associated with interdigital involvement and may extend from the toes across the plantar surface. [2][15]

A painful, macerated, malodorous, or persistently erosive toe web should not be managed as uncomplicated dermatophyte infection alone. Refractory toe-web disease can reflect inadequate treatment, concomitant nail disease, antifungal or antibiotic resistance, or immune deficiency; reassess these branches rather than simply extending empiric topical therapy. [12]

Examine both feet, all interdigital spaces, and toenails at the initial visit. Concurrent onychomycosis can serve as a persistent reservoir and is specifically identified as a contributor to refractory toe-web infection. [12]
- Favor hyperkeratotic tinea pedis when plantar scale and erythema cover the sole while sparing the dorsum. [15]
- Consider inflammatory or bullous tinea pedis when vesicles or bullae are present; demonstrate hyphae with KOH when possible. [2][3]
- Reconsider the diagnosis when plantar erythema is diffuse or treatment-resistant: relevant alternatives include intertrigo, cellulitis, atopic dermatitis, contact dermatitis, eczema, juvenile plantar dermatosis, mycosis fungoides, and pityriasis rubra pilaris. [15]

*Clinical pattern directs expected response time and diagnostic confirmation. [2][15]*

| Pattern | Key distribution clue | Actionable next step |
| --- | --- | --- |
| Interdigital | Pruritic, erythematous, inflamed toe-web disease. [2] | Treat with a topical antifungal; improvement may occur within 1 week. [11][15] |
| Hyperkeratotic moccasin type | Chronic scaly plantar erythema involving soles and lateral feet, often sparing the dorsum. [2][15] | Perform KOH when available; use a longer topical course, typically about 4 weeks. [12][15] |
| Vesicular or bullous | Vesicles or bullae on the sole. [2] | Obtain KOH from active scale or lesion material to document dermatophyte infection. [2][3] |
| Refractory toe-web eruption | Persistent disease despite treatment, especially with nail involvement or maceration. [12] | Culture for fungus; evaluate for bacterial infection, resistance, immune deficiency, and nonfungal mimics. [12][17] |

## Use KOH and culture when the result will redirect management

Testing is most valuable when morphology, severity, or treatment response makes clinical diagnosis unreliable.

Perform a potassium hydroxide preparation from scale at the active edge or involved toe web when hyperkeratotic disease must be distinguished from inflammatory dermatoses, when bullous disease is suspected, or when prior treatment has failed. Identification of bright linear branching hyphae supports dermatophyte infection. [4][6][15]

Clinical diagnosis is often used when KOH is unavailable, but a negative or unavailable bedside test should not indefinitely sustain a diagnosis of tinea in chronic disease. In chronic or recurrent dermatophytosis and when antifungal resistance is suspected, order fungal culture; culture and serial cultures may also help establish mycologic cure in selected patients. [8][17]

If a topical corticosteroid has altered lesion morphology, consider tinea incognito. Look for residual scaly erythematous edges, obtain KOH, and culture chronic, recurrent, or potentially resistant disease. Polymerase chain reaction and matrix-assisted laser desorption ionization-time-of-flight are emerging higher-sensitivity approaches where available. [17]
- Positive KOH: treat as dermatophyte infection and match duration to clinical pattern. [4][6][12][15]
- Persistent disease after an appropriate topical course: obtain fungal culture rather than repeating empiric antifungal cycles. [12][17]
- Follicular papules, pustules, or nodules within a longstanding plaque raise concern for Majocchi granuloma; histopathology is required for conclusive diagnosis. [17]

*Testing strategy for suspected or refractory tinea pedis. [8][12][17]*

| Clinical situation | Test | Interpretation and management consequence |
| --- | --- | --- |
| Typical limited interdigital eruption | Clinical diagnosis may be used; KOH if uncertainty is meaningful. [8][15] | Treat localized disease with a topical antifungal and reassess if it persists. [11][22] |
| Moccasin-type or atypical plantar scale | KOH preparation from involved scale. [4][6][15] | Branching hyphae support dermatophyte infection and help distinguish it from inflammatory plantar dermatoses. [6][15] |
| Chronic, recurrent, or suspected resistant disease | Fungal culture. [17] | Use the result to confirm dermatophytosis and investigate resistance or an alternative diagnosis when response is inadequate. [12][17] |
| Perifollicular papules, pustules, or nodules | Histopathology. [17] | Required to establish Majocchi granuloma, which should not be managed as superficial tinea alone. [17] |

## Treat limited tinea pedis with topical antifungal therapy

Drug choice matters less than adequate coverage, duration, and extension beyond visible disease.

For nonextensive tinea pedis, use terbinafine 1% cream or gel twice daily for 1-2 weeks. Miconazole is an alternative topical regimen applied for 3-4 weeks. A broad evidence base supports topical antifungals over placebo, and terbinafine or naftifine may provide slightly higher cure rates than azoles. [11][22]

Apply cream or powder 1-2 cm beyond visible disease and continue for 1 week after apparent clinical resolution. For hyperkeratotic plantar disease, a 2-3 week or 4-week course may be needed; the longer duration reflects the barrier imposed by thick keratinized skin. [12][15]

Luliconazole 1% is an FDA-approved topical option for interdigital tinea pedis. In pivotal trials, participants applied it once daily for 14 days to the entire forefoot, all interdigital spaces, and approximately 2.5 cm of surrounding skin; outcomes were assessed 4 weeks after treatment. [1]
- Interdigital disease: topical therapy may require only 1 week, depending on the agent and response. [11][15]
- Hyperkeratotic moccasin disease: plan approximately 4 weeks of topical therapy rather than judging failure after a short interdigital-course regimen. [12][15]
- Do not use nystatin for dermatophyte tinea pedis. [11]
- Avoid topical antifungal-corticosteroid combinations when possible because corticosteroid exposure can produce atypical tinea incognito and delay diagnosis. [11][17]

### When to consider oral treatment

Consider oral therapy for severe, chronic, or topical-treatment-refractory tinea pedis. Oral itraconazole or terbinafine are identified options for these circumstances; before escalation, obtain fungal culture in chronic or recurrent disease and evaluate untreated onychomycosis, adherence, bacterial toe-web infection, and alternative diagnoses. [17][20]
- Avoid reflexive systemic escalation for a short course failure in hyperkeratotic disease; first confirm that topical treatment duration and application were adequate. [12][15]
- When nail disease is present, treat the overall dermatophyte burden rather than repeatedly treating the foot alone. [12][20]

*Topical regimens and duration should be matched to disease pattern. [1][11][12][15][22]*

| Option | Source-supported regimen | Best use or limitation |
| --- | --- | --- |
| Terbinafine 1% | Cream or gel twice daily for 1-2 weeks. [22] | First-line option for nonextensive tinea; allylamines may have slightly higher cure rates than azoles. [11][22] |
| Miconazole | Topical treatment for 3-4 weeks. [22] | Alternative for nonextensive tinea when a longer treatment course is acceptable. [22] |
| Luliconazole 1% | Once daily for 14 days; cover entire forefoot, toe webs, and approximately 2.5 cm surrounding area. [1] | FDA-labeled option for interdigital tinea pedis. [1] |
| Any effective topical antifungal | Extend 1-2 cm beyond visible disease and continue 1 week after apparent resolution. [12] | For hyperkeratotic disease, treatment may need 2-4 weeks. [12][15] |

## Work up apparent treatment failure before repeating therapy

Failure usually reflects an incorrect diagnosis, untreated reservoir, inadequate exposure, or complicating infection.

At follow-up, determine whether the initial regimen reached all involved toe webs and plantar surfaces and whether treatment continued beyond visible resolution. For hyperkeratotic disease, an apparent early failure may simply represent insufficient duration because topical penetration is limited by keratinization. [12][15]

If disease is recurrent or persists after an adequate course, perform fungal culture and inspect for onychomycosis. Nail involvement, immune deficiency, and antifungal or antibiotic resistance are recognized contributors to refractory toe-web infection. [12][17]

When toe webs are macerated or otherwise clinically concerning for bacterial involvement, evaluate for mixed infection rather than treating dermatophytes in isolation. Dermatophyte-associated barrier disruption can precede interdigital toe-web infection, and bacterial cultures from interdigital spaces in patients with tinea pedis have recovered potentially pathogenic organisms, commonly group A beta-hemolytic streptococci. [12][21]
- Culture chronic or recurrent disease and suspected resistance. [17]
- Assess for tinea incognito if topical corticosteroids have been used or lesion borders are atypical. [17]
- Biopsy follicular papules, pustules, or nodules when Majocchi granuloma is possible. [17]
- Address concomitant onychomycosis when recurrent pedal disease suggests a nail reservoir. [12][20]

### Prevent recurrence and reduce cellulitis risk

For recurrent tinea pedis, direct prevention toward restoration of toe-web barrier integrity and treatment of persistent reservoirs. Topical antifungals or powders applied beyond visible disease and continued after clearance are used to reduce residual dermatophyte burden; prophylactic antifungals can reduce recurrence. [12]

Control recurrent tinea pedis in patients with recurrent lower-extremity cellulitis. Chronic or recurrent dermatomycosis, including tinea pedis and onychomycosis, is associated with recurrent cellulitis, and foot hygiene should specifically include interdigital web spaces. [21]
- Consider urea cream when thick plantar skin is a suspected recurrent reservoir; use a lower concentration for thin toe-web skin. [12]
- In diabetes, optimize glycemic control as part of recurrence-risk management for fungal skin infection and cellulitis. [21]

*Actions for persistent or recurrent tinea pedis. [12][17][20][21]*

| Problem at reassessment | Immediate action | What changes next |
| --- | --- | --- |
| Hyperkeratotic plantar disease treated briefly | Verify coverage and extend topical treatment to a pattern-appropriate course. [12][15] | Do not label resistance until treatment duration and diagnosis have been reassessed. [12][15] |
| Recurrent disease with dystrophic toenails | Examine for onychomycosis and address nail involvement. [12][20] | Treating the nail reservoir may be necessary to control recurrent foot disease. [12][20] |
| Persistent disease despite adequate topical treatment | Obtain fungal culture. [17] | Confirm dermatophytosis and evaluate resistant infection or alternative diagnoses. [12][17] |
| Macerated or complicated toe webs | Assess for bacterial co-infection and barrier disruption. [12][21] | Manage mixed infection rather than escalating antifungal therapy alone. [12][21] |
| Recurrent cellulitis | Treat tinea pedis and reinforce interdigital foot hygiene. [21] | Reduce a modifiable dermatologic contributor to recurrent cellulitis. [21] |

## References
1. These highlights do not include all the information needed to use Luliconazole Cream safely and effectively. See full prescribing information for Luliconazole Cream.
      Luliconazole cream, for topical useInitial U.S. Approval: 2013 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7ccda3ba-9c98-468d-83c6-7f0cc7c88c33
2. [PDF] Cross Discipline Team Leader Review - FDA — www.fda.gov — https://www.fda.gov/media/111591/download
3. Inflammatory Tinea Pedis/Manuum Masquerading as Bacterial ... — jamanetwork.com — https://jamanetwork.com/journals/jamapediatrics/fullarticle/204100
4. A Better Potassium Hydroxide Preparation? In Vivo Diagnosis of ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/478452
5. Tinea Pedis in Children - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jamapediatrics/articlepdf/516240/archpedi_146_7_025.pdf?resultClick=1
6. A Better Potassium Hydroxide Preparation? - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/DERM/articlepdf/478452/dob00036.pdf
7. How effective is topical miconazole or amorolfine for mild to moderately severe onychomycosis in primary care: the Onycho Trial – a randomised double-blind placebo-controlled trial | BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/14/5/e081914
8. Dermatophyte infections - Symptoms, diagnosis and treatment — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/119
9. Prevalence and risk factors of tinea pedis in Georgian Defense Forces — militaryhealth.bmj.com — https://militaryhealth.bmj.com/cgi/rapidpdf/bmjmilitary-2019-001397?ijkey=0j9z8tMzFfLYqSb&keytype=ref
10. Tinea manuum: a 5 year retrospective study of demographic data, clinical characteristics, and treatment outcomes | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-87011-w
11. Management of tinea corporis, tinea cruris, and tinea... : Indian Dermatology Online Journal — journals.lww.com — https://journals.lww.com/idoj/fulltext/2016/07020/management_of_tinea_corporis,_tinea_cruris,_and.2.aspx
12. Toe Web Infections, the Microbiome, and Toe Web Psoriasis:... — journals.lww.com — https://journals.lww.com/aswcjournal/fulltext/2023/07000/toe_web_infections%25252C_the_microbiome%25252C_and_toe_web.8.aspx
13. Major challenges in dermatophytosis treatment : Egyptian Journal of Dermatology and Venereology — journals.lww.com — https://journals.lww.com/ejdv/fulltext/2021/41010/major_challenges_in_dermatophytosis_treatment_.1.aspx
14. Indian Association of Dermatologists,... : Indian Dermatology Online Journal — journals.lww.com — https://journals.lww.com/idoj/_layouts/15/oaks.journals/downloadpdf.aspx?an=01630814-202011040-00004
15. Flexibility is warranted in applying prescribing guidelines ... — www.ccjm.org — https://www.ccjm.org/content/ccjom/92/9/local/complete-issue.pdf
16. Fungal Skin Infections - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/825736
17. Tinea incognito | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/92/5/271
18. Fungal Skin Infections | Pediatrics In Review - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/38/1/8/35002/Fungal-Skin-Infections
19. Tinea Corporis(Ringworm of the Body) - AAP Publications — publications.aap.org — https://publications.aap.org/aapbooks/book/723/chapter/10679895/Tinea-Corporis-Ringworm-of-the-Body
20. Tinea Pedis and Tinea Unguium - AAP Publications — publications.aap.org — https://publications.aap.org/books/chapter-pdf/1297872/aap_9781581107357-part03-tinea4.pdf
21. Recurrent Cellulitis: Who is at Risk and How Effective is Antibiotic P | IJGM | Dove Medical Press — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2147%2FIJGM.S326459&link_type=DOI
22. [PDF] Guidelines on the treatment of skin and oral HIV-associated ... - IRIS — iris.who.int — https://iris.who.int/server/api/core/bitstreams/50196a71-51c6-4e05-ade2-36e013a450fe/content
23. [PDF] Minutes of PRAC meeting on 08-11 June 2026 — www.ema.europa.eu — https://www.ema.europa.eu/fr/media/75190
24. Topical antifungal treatments for tinea cruris and ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009992.pub2/references

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.